Opinion: Boycotting Elsevier Is Not Enough

The publishing giant will likely survive the latest boycott by scientists. An overhaul is needed to make science publishing fair and open.

Written byShaun Khoo
| 4 min read
boycott petition elsevier academic scholarly publishing open access

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

ABOVE: © ISTOCK.COM, LEREMY

All of this has happened before. A group of scientists, upset with the extraordinarily profitable Elsevier, have announced its intention to boycott the publisher. In 2012, mathematicians led the Cost of Knowledge boycott. This time, it’s University of California (UC) scientists upset about the breakdown of negotiations that sought to combine journal subscriptions with open-access publishing. Unfortunately, on its own, this boycott will do little to change science publishing.

Many scientists struggle to see the value Elsevier provides. Elsevier usually demands a high price to publish a paper—on the order of $4,000–$5,000—and has also shown a willingness to play hardball in negotiations with whole countries. Importantly, Elsevier’s authors, reviewers, and most editors never receive any of this money.

Boycotting Elsevier is therefore a reasonable response from dissatisfied stakeholders. In theory, if boycotters provide their authoring, reviewing, and editing expertise for publishers with better copyright and access ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies